CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
transdermal nicotine patch +1 moredrug
Likely dose
transdermal nicotine patch 14mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00383747
NCT00383747Phase 4Completed
CompareCT.gov

A Double Blind Placebo Controlled Trial of the Effects of Transdermal Nicotine on Cognitive Function in Non-Smokers With and Without Schizophrenia

Massachusetts General Hospital·interventional·Posted Oct 3, 2006·Updated Apr 28, 2017

In Brief

A Phase 4 clinical trial evaluating transdermal nicotine patch and Transdermal Nicotine Patch for Schizophrenia. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We will evaluate the effects of transdermal nicotine compared with placebo for attentional impairments in non-smokers with schizophrenia and controls.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsStanley Medical Research Institute, North Suffolk Mental Health Association

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 3, 2006
Enrollment StartApr 1, 2004
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.7 years ago

Interventions

transdermal nicotine patchdrug

14mg transdermal nicotine application

Transdermal Nicotine Patchdrug

14mg transdermal nicotine application